AR063120A1 - INJECTABLE DEPOSIT COMPOSITIONS AND PROCESS TO PREPARE THEM - Google Patents

INJECTABLE DEPOSIT COMPOSITIONS AND PROCESS TO PREPARE THEM

Info

Publication number
AR063120A1
AR063120A1 ARP070104388A ARP070104388A AR063120A1 AR 063120 A1 AR063120 A1 AR 063120A1 AR P070104388 A ARP070104388 A AR P070104388A AR P070104388 A ARP070104388 A AR P070104388A AR 063120 A1 AR063120 A1 AR 063120A1
Authority
AR
Argentina
Prior art keywords
component
optionally
active agent
compositions
mixing
Prior art date
Application number
ARP070104388A
Other languages
Spanish (es)
Inventor
Kour Chand Jindal
Sampath Kumar Devarajan
Rajesh Jain
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR063120A1 publication Critical patent/AR063120A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones inyectables de deposito que comprenden al menos un agente activo, opcionalmente con uno o.más excipientes farmacéuticamente aceptables en forma de un sistema de componentes multiples que comprende preferiblemente al menos dos componentes que, al ser suministrados a un individuo que los necesita, forma un deposito de gel in situ o implante en el lugar de la inyeccion tras el contacto con fluidos corporales y exhibe una liberacion prolongada del agente activo. Proceso para preparacion de tales composiciones y métodos para usar dichas composiciones. Reivindicacion 4: Una composicion tal como se reivindica en la reivindicacion 1, caracterizada porque el agente activo se selecciona de un grupo que comprende anastrozola, lentrozola, tamsulosin, donepezil, aripiprazol, olanzapina, risperidona y ziprasidona. Reivindicacion 25: Un proceso para la preparacion de una composicion inyectable tal como se reivindica en la reivindicacion 7, caracterizado por comprender los siguientes pasos: i) mezclar el agente(s) activo con polímero(s) biodegradable para formar micropartículas o nanopartículas, (ii) mezclas las micropartículas o nanopartículas del paso (i) opcionalmente con agente(s) mejoradotes de la viscosidad y/u opcionalmente con uno o más excipientes para formar el componente 1, (iii) mezclar el vehículo líquido opcionalmente con agente(s) mejorador(es) de la viscosidad y/u otros excipientes para formar el componente 2, y (iv) mezclar el componente 1 y el componente 2 para obtener el compuesto deseado antes de la administracion.Injectable depot compositions comprising at least one active agent, optionally with one or more pharmaceutically acceptable excipients in the form of a multi-component system preferably comprising at least two components which, when supplied to an individual in need, forms a gel deposit in situ or implant at the injection site after contact with body fluids and exhibits a prolonged release of the active agent. Process for preparing such compositions and methods for using said compositions. Claim 4: A composition as claimed in claim 1, characterized in that the active agent is selected from a group comprising anastrozole, lentrozole, tamsulosin, donepezil, aripiprazole, olanzapine, risperidone and ziprasidone. Claim 25: A process for the preparation of an injectable composition as claimed in claim 7, characterized by comprising the following steps: i) mixing the active agent (s) with biodegradable polymer (s) to form microparticles or nanoparticles, ( ii) mixing the microparticles or nanoparticles of step (i) optionally with viscosity enhancing agent (s) and / or optionally with one or more excipients to form component 1, (iii) optionally mixing the liquid vehicle with agent (s) viscosity improver (s) and / or other excipients to form component 2, and (iv) mix component 1 and component 2 to obtain the desired compound before administration.

ARP070104388A 2006-10-05 2007-10-03 INJECTABLE DEPOSIT COMPOSITIONS AND PROCESS TO PREPARE THEM AR063120A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2195DE2006 2006-10-05

Publications (1)

Publication Number Publication Date
AR063120A1 true AR063120A1 (en) 2008-12-30

Family

ID=39268891

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104388A AR063120A1 (en) 2006-10-05 2007-10-03 INJECTABLE DEPOSIT COMPOSITIONS AND PROCESS TO PREPARE THEM

Country Status (17)

Country Link
US (2) US20100015195A1 (en)
EP (2) EP2089000A2 (en)
JP (2) JP2010505821A (en)
KR (2) KR20090087441A (en)
CN (2) CN101541316A (en)
AR (1) AR063120A1 (en)
AU (2) AU2007303794A1 (en)
BR (2) BRPI0718288A2 (en)
CA (2) CA2665105A1 (en)
CL (1) CL2007002851A1 (en)
EA (1) EA200970348A1 (en)
IL (2) IL197947A0 (en)
MA (2) MA30814B1 (en)
MX (2) MX2009003737A (en)
RU (1) RU2009116933A (en)
TN (2) TN2009000125A1 (en)
WO (2) WO2008041246A2 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP2526996B1 (en) 2002-12-20 2019-09-11 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CN101801415B (en) 2007-05-25 2015-09-23 Rb医药品有限公司 The sustained delivery formulations of risperidone compounds
MX2009013663A (en) * 2007-06-22 2010-01-27 Scidose Llc Solubilized formulation of docetaxel without tween 80.
ES2529746T3 (en) * 2007-06-25 2015-02-25 Otsuka Pharmaceutical Co., Ltd. Microspheres with a core / shell structure
CL2008003305A1 (en) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Injectable composition comprising an active agent selected from a defined group; at least one bioerodible polymer, at least one non-toxic solvent and optionally one or more excipients; Preparation process; use to treat mental illness or cancer.
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US9180088B2 (en) 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CN101569622B (en) * 2008-04-30 2012-11-21 天津药物研究院 Pharmaceutical preparation for injection administration and preparation method thereof
EA014044B1 (en) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Nanosomal pharmaceutical form of a long acting preparation for treating hepatitis c (variants)
AU2009289529B2 (en) * 2008-09-04 2015-05-28 Amylin Pharmaceuticals, Llc Sustained release formulations using non-aqueous carriers
CN102281870B (en) 2008-12-10 2015-03-04 安徽中人科技有限责任公司 Novel controlled releasing composition
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
CA2754200A1 (en) * 2009-03-02 2010-09-10 Assistance Publique - Hopitaux De Paris Injectable biomaterial
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN104323981B (en) 2009-09-28 2019-03-12 精达制药公司 The quick foundation and/or termination of basic steady-state drug delivery
CN101669942A (en) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 Insoluble pharmaceutical composition
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
RU2548753C2 (en) 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Pharmaceutical compositions of melanocortin receptor ligands
EP2547351B1 (en) * 2010-03-15 2016-04-27 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
RU2012145811A (en) * 2010-03-29 2014-05-10 Евоник Корпорейшн COMPOSITIONS AND METHODS OF IMPROVED RETAINING OF THE PHARMACEUTICAL COMPOSITION AT THE LOCAL INTRODUCTION SECTION
US10335366B2 (en) * 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
ES2390439B1 (en) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DE102010023949A1 (en) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ lecithin microemulsion gel formulation
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
CA2796755C (en) * 2010-08-24 2015-10-27 Otsuka Pharmaceutical Co., Ltd. Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
JP5966228B2 (en) * 2010-10-28 2016-08-10 アエクース ファーマシューティカルズ インコーポレイテッドＡｅｑｕｕｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ Aripiprazole composition
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG193389A1 (en) 2011-03-10 2013-10-30 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs
US9034867B2 (en) * 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CN103930096B (en) 2011-10-31 2017-05-31 Xeris药物公司 Preparation for treating diabetes
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JOP20200109A1 (en) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd Injectable preparation
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CN103483353B (en) * 2012-06-13 2016-02-24 上海现代药物制剂工程研究中心有限公司 Dithiole the nanoparticle of pyrrolidone compound and preparation method
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
KR101811797B1 (en) * 2013-04-03 2017-12-22 동국제약 주식회사 Pharmaceutical composition comprising donepezil for parenteral administration
US9949928B2 (en) * 2013-05-01 2018-04-24 The Regents Of The University Of Colorado, A Body Corporate Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
US20160200891A1 (en) * 2013-08-22 2016-07-14 Polyvalor Limited Partnership Porous gels and methods for their preparation
JP2015093854A (en) * 2013-11-12 2015-05-18 株式会社クレハ Aqueous composition and method for inhibiting hydrolysis
CH708890B1 (en) * 2013-11-22 2018-03-15 Sandel Thomas Ball, preferably golf ball, and a communicable with the ball electronic device.
US20150174254A1 (en) 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
CA2957399C (en) 2014-08-06 2023-09-26 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20170083108A (en) * 2014-11-10 2017-07-17 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Long acting pharmaceutical compositions for hepatitis c
EP3028721A1 (en) * 2014-12-05 2016-06-08 Exchange Imaging Technologies GmbH Nanoparticle formulation having reverse-thermal gelation properties for injection
KR101692314B1 (en) * 2015-03-27 2017-01-03 주식회사 주빅 Dissolution system of lipophilic drugs into biodegradable polymer: Smart Polymer System
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP3373907A4 (en) * 2015-11-11 2019-12-18 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
CN115120405A (en) 2016-04-20 2022-09-30 多斯医学公司 Delivery device for bioabsorbable ocular drugs
WO2017200987A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
MX2018014016A (en) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof.
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
EP3573747A4 (en) * 2017-01-23 2020-12-30 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
CN106822043A (en) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 risperidone slow-release composition and preparation method thereof
CN106822039A (en) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 Shipwreck is molten or microsolubility pharmaceutical sustained release compositions and preparation method thereof
CN106822042A (en) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 A kind of risperidone slow-release composition and preparation method thereof
CN106727422B (en) * 2017-03-09 2018-10-02 王秋玉 A kind of polydioxanone is the core-shell structure copolymer bilayer microballoon and its preparation method and application of core
WO2018222922A1 (en) 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
KR20200091385A (en) 2017-09-15 2020-07-30 옥슬러 리미티드 Ophthalmic delivery device
PL3562485T3 (en) * 2018-03-23 2020-11-16 Laboratoires Major Non-hormonal compositions and methods for male contraception comprising (r)-silodosin
PE20210047A1 (en) 2018-06-12 2021-01-08 Farm Rovi Lab Sa INJECTABLE COMPOSITION
JP2021534242A (en) * 2018-08-10 2021-12-09 エフェメラル ソリューションズ，インコーポレイテッド Particles containing colorants and how to use them
US11896715B2 (en) 2019-06-21 2024-02-13 Korea University Research And Business Foundation In vivo bulking agent, injection comprising same, and preparation method therefor
CN111388744B (en) * 2020-01-15 2021-05-18 华中科技大学 Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation
CN111956599B (en) * 2020-09-29 2023-02-17 江苏集萃新型药物制剂技术研究所有限公司 Subcutaneous implant medicine and its composition and preparation method
KR102266384B1 (en) * 2021-01-25 2021-06-21 주식회사 울트라브이 Biodegradable polymer fine particles for filler, freeze-dried product for filler including the same, preparing method thereof, injection for filler including the freeze-dried product
KR102652905B1 (en) * 2021-08-09 2024-04-01 주식회사 메디폴리머 Injectablepre-forumulation and kit with reduced initial donepezil release using the same
TW202313047A (en) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 Antipsychotic injectable depot composition
WO2024151625A1 (en) * 2023-01-10 2024-07-18 Georgetown University Non-toxic plga compositions and methods of making and using same
CN116850146B (en) * 2023-05-22 2024-05-14 济南大学 Sustained release preparation of free base of voathixetine or its medicinal salt and its preparation method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
ATE188375T1 (en) * 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical A SUSTAINED RELEASE MICROBLADE CONTAINING AN ANTIPSYCHOTIC AND METHOD FOR THE PRODUCTION THEREOF
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
WO2002058672A2 (en) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
BRPI0213226B1 (en) * 2001-10-10 2016-03-01 Pf Medicament process of preparing a pharmaceutical composition in the form of extended release microspheres of a water soluble active ingredient, and, microspheres
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms

Also Published As

Publication number Publication date
RU2009116933A (en) 2010-11-10
CL2007002851A1 (en) 2008-01-18
KR20090087441A (en) 2009-08-17
US20100015195A1 (en) 2010-01-21
CA2665105A1 (en) 2008-04-10
BRPI0718288A2 (en) 2013-11-19
CN101541316A (en) 2009-09-23
JP2010505819A (en) 2010-02-25
JP2010505821A (en) 2010-02-25
IL197947A0 (en) 2009-12-24
EP2086505A2 (en) 2009-08-12
AU2007303794A1 (en) 2008-04-10
MA30817B1 (en) 2009-10-01
EP2089000A2 (en) 2009-08-19
MA30814B1 (en) 2009-10-01
CN101541313A (en) 2009-09-23
CA2665101A1 (en) 2008-04-10
TN2009000124A1 (en) 2010-10-18
WO2008041245A2 (en) 2008-04-10
IL197946A0 (en) 2009-12-24
MX2009003735A (en) 2009-04-22
WO2008041245A3 (en) 2008-05-22
WO2008041246A2 (en) 2008-04-10
TN2009000125A1 (en) 2010-10-18
AU2007303793A1 (en) 2008-04-10
WO2008041246A3 (en) 2008-05-29
US20100098735A1 (en) 2010-04-22
KR20090094811A (en) 2009-09-08
EA200970348A1 (en) 2009-10-30
BRPI0720346A2 (en) 2014-06-24
MX2009003737A (en) 2009-06-16

Similar Documents

Publication Publication Date Title
AR063120A1 (en) INJECTABLE DEPOSIT COMPOSITIONS AND PROCESS TO PREPARE THEM
HRP20180118T1 (en) Injectable flowable composition comprising buprenorphine
ES2524320T3 (en) Composition for the prevention or treatment of disease associated with thrombus or embolus
WO2009044403A3 (en) Injectable biodegradable polymer compositions for soft tissue repair and augmentation
AR070033A1 (en) INJECTABLE COMPOSITIONS, THEIR PROCESSES AND USES
AR041913A1 (en) CONTROLLED RELEASE DEPOSIT FORMULATIONS
JP2013533230A5 (en)
MY161930A (en) Antipsychotic injectable depot composition
BRPI0514297A (en) pharmaceutical compositions for controlled release of biologically active compounds
BR112015017246A2 (en) pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
AR060487A1 (en) PHARMACEUTICAL COMPOSITIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40
PE20060003A1 (en) POLYMERIC PHARMACEUTICAL FORMULATION FOR INJECTION MOLDING
BR112012030457A2 (en) process for making a dry and stable hesostatic composition, method for delivering a hemostatic composition to a target site and providing a ready-to-use hemostatic composition, finished finished container, and kit for administering a hemostatic composition
HRP20161138T1 (en) Pharmaceutical composition for oral administration
BR112014013691A2 (en) preformulation, methods for delivery of a peptide active agent, for the preparation of a liquid crystalline composition, treatment or prophylaxis of a subject, process for forming a preformulation, use of a low liquid crystalline mixture viscosity, pre-filled delivery device, and kit
CR9704A (en) PHARMACEUTICAL COMPOSITION OF MODIFIED LIBERATION, PREPARATION PROCESS AND METHOD TO USE THE SAME.
WO2007084460A3 (en) Pharmaceutical compositions with enhanced stability
BR112013027674A2 (en) "uses of nanoparticle compositions, compositions comprising said nanoparticles and single needle catheter".
NZ627368A (en) Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
AR072668A1 (en) ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS
AR082566A1 (en) LIQUID FORMULATIONS OF ST-246 AND RELATED METHODS, PROCESS
WO2007111945A3 (en) Method for management of diarrhea
BR112016001544A2 (en) pharmaceutical compositions for intraocular injection comprising antibacterial and anti-inflammatory agents, their method of preparation, pharmaceutical kit and use of said agents in the preparation of said pharmaceutical compositions
JP2018510894A5 (en)
AR066677A1 (en) FORMATION OF PASSIREOTIDE. PHARMACEUTICAL COMPOSITION FOR PROLONGED RELEASE. MICROPARTICLES.

Legal Events

Date Code Title Description
FB Suspension of granting procedure